Skip to content
Study details
Enrolling now

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Pfizer
NCT IDNCT05995964ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

340

Study length

about 3.3 years

Ages

18+

Locations

52 sites in AL, AZ, CA +16

About this study

Researchers are testing two trial medicines, PF-07275315 and PF-07264660, in people with moderate to severe atopic dermatitis. It is seeking participants who have confirmed atopic dermatitis for at least 6 months and are not having an effective treatment result from medicines that are applied on skin for AD. Participants will receive either PF-07275315 or PF-07264660 or placebo as multiple shots in the clinic over the course of each Stage.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take PF-07264660
  • 3.Take PF-07275315
PhasePhase 2

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: The number and % of participants achieving a Percent change from baseline in EASI total score at scheduled time points, The number and % of participants with treatment emergent AEs

Body systems

Dermatology